J&J/Ethicon Endo-Surgery Weighs Breast Care Divestiture To Devicor
This article was originally published in The Gray Sheet
Executive Summary
Devicor Medical Products is seeking a foothold in the device market with its proposed acquisition of Johnson & Johnson/Ethicon Endo-Surgery's breast care business, the company announced March 30
You may also be interested in...
J&J sells breast care unit to Devicor
Johnson & Johnson's Ethicon Endo-Surgery unit completes the divestiture of its breast care business to Devicor Medical Products on July 12. Devicor's acquisition of the vacuum-assisted breast biopsy device maker, for undisclosed terms, includes the flagship Mammotome breast biopsy system (1"The Gray Sheet" April 5, 2010)
J&J sells breast care unit to Devicor
Johnson & Johnson's Ethicon Endo-Surgery unit completes the divestiture of its breast care business to Devicor Medical Products on July 12. Devicor's acquisition of the vacuum-assisted breast biopsy device maker, for undisclosed terms, includes the flagship Mammotome breast biopsy system (1"The Gray Sheet" April 5, 2010)
Start-Up Quarterly Statistics, Q1 2010
Highlights from the Q1 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $331 million, a 66% drop from the previous quarter's $976 million, and a 52% slide from Q1 2009. As was the case in Q4 2009, Series B rounds dominated in the biopharma and device sectors. Just one acquisition closed in the quarter - BioMarin buying LEAD Therapeutics - however two others are in the works. On the alliance front, SpePharm and Dicerna each signed two deals in Q1.